Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: A retrospective, observational study

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 9, 2012, Pages 3251-3260

  Morgan, Christopher L ^b   Jenkins Jones, Sara ^a   Currie, Craig J ^b   Rees, D Aled ^b  

^a Pharmatelligence   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVERSE OUTCOME; ARTICLE; BODY MASS; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OVARY POLYCYSTIC DISEASE; PATIENT ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; UNITED KINGDOM;

ADULT; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; NEOPLASMS; PERIPHERAL VASCULAR DISEASES; POLYCYSTIC OVARY SYNDROME; PRIMARY HEALTH CARE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SMOKING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866170600     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1690     Document Type: Article

References (40)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO 2004 The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745-2749 (Pubitemid 38766360)
2. Franks S 1995 Polycystic ovary syndrome. N Engl J Med 333:853-861
3. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS 1995 Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of noninsulin dependent diabetes mellitus. J Clin Invest 96:520-527
4. Dunaif A 1997 Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774-800 (Pubitemid 28009567)
5. Legro RS, Kunselman AR, Dodson WC, Dunaif A 1999 Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165-169 (Pubitemid 29036695)
6. Elting MW, Korsen TJ, Bezemer PD, Schoemaker J 2001 Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 16:556-560 (Pubitemid 32218809)
7. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A 2005 Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 90:3236-3242 (Pubitemid 41014281)
8. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ 2001 Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 16:1995-1998 (Pubitemid 32916235)
9. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J 1999 Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:141-146 (Pubitemid 29028311)
10. Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN 2005 Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:66-71 (Pubitemid 40116635)
11. Pollak MN, Schernhammer ES, Hankinson SE 2004 Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505-518 (Pubitemid 38868620)
12. Calle EE, Kaaks R 2004 Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579-591 (Pubitemid 39025053)
13. Barber TM, Golding SJ, Alvey C, Wass JA, Karpe F, Franks S, McCarthy MI 2008 Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab 93:999-1004 (Pubitemid 351398585)
14. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L 1995 Coronary heart disease risk factors inwomenwith polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 15:821-826
15. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS 1996 Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 45:623-629 (Pubitemid 26411365)
16. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD 2001 Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103:1410-1415 (Pubitemid 32220633)
17. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH 2000 Evidence for the association between polycystic ovary syndrome and premature carotid atherosclerosis in middle aged women. Arterioscler Thromb Vasc Biol 20:2414-2421
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR 1987 A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373-383 (Pubitemid 17055592)
19. Moran LJ, Misso ML, Wild RA, Norman RJ 2010 Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 16:347-363
20. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE 2005 Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:1929-1935 (Pubitemid 40586223)
21. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN 2006 Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 91:48-53 (Pubitemid 43069116)
22. Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Ronsisvalle E, Guido M, Caruso A, Lanzone A 1999 Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism 48:167-172 (Pubitemid 29072269)
23. Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creatsas G 2006 Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril 85:420-427 (Pubitemid 43170917)
24. Meyer C, McGrath BP, Teede HJ 2007 Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 30:471-478 (Pubitemid 46354320)
25. Lord JM, Flight IH, Norman RJ 2003 Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327:951-953
26. Sharma ST, Wickham 3rd EP, Nestler JE 2007 Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. Endocr Pract 13:373-379
27. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA 2005 Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 90:2545-2549 (Pubitemid 40686289)
28. Speert H 1949 Carcinoma of the endometrium in young women. Surg Gynecol Obstet 88:332-336
29. Dockerty MB, Loveday SB, Foust GT 1951 Carcinoma of the corpus uteri in young women. Am J Obstet Gynecol 61:966-981
30. Hardiman P, Pillay OC, Atiomo W 2003 Polycystic ovary syndrome and endometrial carcinoma. Lancet 361:1810-1812 (Pubitemid 36638434)
31. Fader AN, Arriba LN, Frasure HE, von Gruenigen VE 2009 Endometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 114:121-127
32. Fearnley EJ, Marquart L, Spurdle AB, Weinstein P, Webb PM; Australian Ovarian Cancer Study Group and the Australian National Endometrial Cancer Study Group 2010 Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control 21:2303-2308
33. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS 2004 Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:5454-5461 (Pubitemid 39518426)
34. Meyer C, McGrath BP, Teede HJ 2005 Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 90:5711-5716 (Pubitemid 41415480)
35. Agarwal N, Rice SP, Bolusani H, Luzio SD, Dunseath G, Ludgate M, Rees DA 2010 Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 95:722-730
36. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ 2008 Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 93:1276-1284 (Pubitemid 351519721)
37. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS 1998 Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51:581-586 (Pubitemid 28376967)
38. Wild S, Pierpoint T, McKeigue P, Jacobs H 2000 Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 52:595-600 (Pubitemid 30337085)
39. Ketel IJ, Stehouwer CD, Henry RM, Serné EH, Hompes P, Homburg R, Smulders YM, Lambalk CB 2010 Greater arterial stiffness in polycystic ovary syndrome (PCOS) is an obesity- but not a PCOS-associated phenomenon. J Clin Endocrinol Metab 95:4566-4575
40. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE 2007 Glucose intolerance in polycystic ovary syndrome: a position statement of the Androgen Excess Society. J Clin Endocrinol Metab 92:4546-4556 (Pubitemid 350223423)